Recent Company News

• 03:03 AM ET Jul 02, 2025
  

  Belite Bio completes enrollment in Phase 3 PHOENIX trial of Tinlarebant ($57.16, 0.00)

• 05:09 PM ET May 21, 2025
  

  StreetAccount Sector Summary - Healthcare Post-Market

• 03:02 AM ET May 21, 2025
  

  FDA grants Breakthrough Therapy Designation for Belite Bio's tinlarebant to treat Stargardt Disease ($64.81, 0.00)

• 09:03 PM ET May 13, 2025
  

  Belite Bio reports Q1 EPS ($0.45) vs FactSet ($0.35) [5 est, ($0.44)-(0.30)] ($60.89, 0.00)

• 06:02 AM ET Mar 17, 2025
  

  Belite Bio reports Q4 EPS ($0.32) vs FactSet ($0.31) [5 est, ($0.32)-(0.29)] ($67.45, 0.00)

• 02:08 AM ET Feb 27, 2025
  

  DSMB recommends DRAGON trial of Belite Bio's Tinlarebant proceed without modifications; webcast at 16:30 ET ($55.50, 0.00)

• 01:30 PM ET Feb 14, 2025
  

  StreetAccount Summary: Notable Drug Events expected for the week of 16-Feb

• 01:30 PM ET Feb 07, 2025
  

  StreetAccount Summary: Notable Drug Events expected for the week of 9-Feb

• 10:37 PM ET Feb 05, 2025
  

  Belite Bio enters into $15M ADSs-and-warrants registered direct offering ($58.07, 0.00)

• 02:29 PM ET Jan 31, 2025
  

  StreetAccount Summary: Notable Drug Events expected for the week of 2-Feb